Patient derived primary materials have a high potential for accelerating fundamental and translational science, via biomarker and drug discovery, development of personalized medicine, and many more applications.

Heleen Sonneveld van Kooten is coordinator of the biobank at the Centre for Living Technologies in UMC Utrecht. She discusses interesting aspects about biobanks and its impact on translational medicine in this article.